Angiotensin II type I and prostaglandin F2α receptors cooperatively modulate signaling in vascular smooth muscle cells

Journal of Biological Chemistry

Volumn 290, Issue 5, 2015, Pages 3137-3148

  Goupil, Eugénie ^a,e   Fillion, Dany ^a   Clément, Stéphanie ^a   Luo, Xiaoyan ^d   Devost, Dominic ^a   Sleno, Rory ^a   Pétrin, Darlaine ^a   Saragovi, H Uri ^a,c   Thorin, Éric ^d   Laporte, Stéphane A ^a,b   Hébert, Terence E ^a  

^a MCGILL UNIVERSITY   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

^e INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD PRESSURE; CELLS; CHEMICAL ACTIVATION; LIPIDS; MUSCLE; SIGNALING;

ANGIOTENSIN II; AORTIC RINGS; CO TREATMENTS; HETERODIMERIC COMPLEXES; INOSITOL PHOSPHATE; PHYSICAL INTERACTIONS; SIGNALING UNITS; VASCULAR SMOOTH MUSCLE CELLS;

CELL SIGNALING;

ANGIOTENSIN 2 RECEPTOR TYPE 1; PROSTAGLANDIN F2 ALPHA RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR; PROSTAGLANDIN F2ALPHA RECEPTOR; PROSTAGLANDIN RECEPTOR;

ABDOMINAL AORTA; ALLOSTERISM; ANIMAL CELL; ARTICLE; BLOOD PRESSURE REGULATION; CELL GROWTH; CONTROLLED STUDY; DIMERIZATION; EMBRYO; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR BLOCKING; RECEPTOR OCCUPANCY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; ANIMAL; CELL CULTURE; HEK293 CELL LINE; METABOLISM; PHYSIOLOGY;

ALLOSTERIC REGULATION; ANIMALS; CELLS, CULTURED; HEK293 CELLS; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, PROSTAGLANDIN; SIGNAL TRANSDUCTION;

EID: 84921875408     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.631119     Document Type: Article

References (56)

1. Makino, S., Zaragoza, D. B., Mitchell, B. F., Robertson, S., and Olson, D. M. (2007) Prostaglandin F2α and its receptor as activators of human decidua. Semin. Reprod. Med. 25, 60-68
2. Olson, D. M. (2003) The role of prostaglandins in the initiation of parturition. Best Pract. Res. Clin. Obstet. Gynaecol. 17, 717-730
3. Lee, P. Y., Shao, H., Xu, L. A., and Qu, C. K. (1988) The effect of prostaglandin F2α on intraocular pressure in normotensive human subjects. Invest. Ophthalmol. Vis. Sci. 29, 1474-1477
4. Bos, C. L., Richel, D. J., Ritsema, T., Peppelenbosch, M. P., and Versteeg, H. H. (2004) Prostanoids and prostanoid receptors in signal transduction. Int. J. Biochem. Cell Biol. 36, 1187-1205
5. Goupil, E., Tassy, D., Bourguet, C., Quiniou, C., Wisehart, V., Pétrin, D., Le Gouill, C., Devost, D., Zingg, H. H., Bouvier, M., Saragovi, H. U., Chemtob, S., Lubell, W. D., Claing, A., Hébert, T. E., and Laporte, S. A. (2010) A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2α-mediated Rho/ROCK signaling pathway. J. Biol. Chem. 285, 25624-25636
6. Fujino, H., Srinivasan, D., Pierce, K. L., and Regan, J. W. (2000) Differential regulation of prostaglandin F2α receptor isoforms by protein kinase C. Mol. Pharmacol. 57, 353-358
7. Critchley, H. O., Osei, J., Henderson, T. A., Boswell, L., Sales, K. J., Jabbour, H. N., and Hirani, N. (2006) Hypoxia-inducible factor-1α expression in human endometrium and its regulation by prostaglandin E-series prostanoid receptor 2 (EP2). Endocrinology 147, 744-753
8. Goupil, E., Wisehart, V., Khoury, E., Zimmerman, B., Jaffal, S., Hébert, T. E., and Laporte, S. A. (2012) Biasing the prostaglandin F2α receptor responses toward EGFR-dependent transactivation of MAPK. Mol. Endocrinol. 26, 1189-1202
9. Yu, Y., Lucitt, M. B., Stubbe, J., Cheng, Y., Friis, U. G., Hansen, P. B., Jensen, B. L., Smyth, E. M., and FitzGerald, G. A. (2009) Prostaglandin F2α elevates blood pressure and promotes atherosclerosis. Proc. Natl. Acad. Sci. U.S.A. 106, 7985-7990
10. Griffin, B. W., Magnino, P. E., Pang, I. H., and Sharif, N. A. (1998) Pharmacological characterization of an FP prostaglandin receptor on rat vascular smooth muscle cells (A7r5) coupled to phosphoinositide turnover and intracellular calcium mobilization. J. Pharmacol. Exp. Ther. 286, 411-418
11. Griendling, K. K., Ushio-Fukai, M., Lassègue, B., and Alexander, R. W. (1997) Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 29, 366-373
12. Berk, B. C. (1999) Angiotensin II signal transduction in vascular smooth muscle: pathways activated by specific tyrosine kinases. J. Am. Soc. Nephrol. 10, S62-S68
13. Zimmerman, B., Simaan, M., Akoume, M. Y., Houri, N., Chevallier, S., Séguéla, P., and Laporte, S. A. (2011) Role of βarrestins in bradykinin B2 receptor-mediated signalling. Cell. Signal. 23, 648-659
14. Zhang, X., Wang, G., Dupré, D. J., Feng, Y., Robitaille, M., Lazartigues, E., Feng, Y. H., Hébert, T. E., and Wu, G. (2009) Rab1 GTPase and dimerization in the cell surface expression of angiotensin II type 2 receptor. J. Pharmacol. Exp. Ther. 330, 109-117
15. Speth, R. C., and Harding, J. W. (2001) Radiolabeling of angiotensin peptides. Methods Mol. Med. 51, 275-295
16. Servant, G., Laporte, S. A., Leduc, R., Escher, E., and Guillemette, G. (1997) Identification of angiotensin II-binding domains in the rat AT2 receptor with photolabile angiotensin analogs. J. Biol. Chem. 272, 8653-8659
17. Laporte, S. A., Servant, G., Richard, D. E., Escher, E., Guillemette, G., and Leduc, R. (1996) The tyrosine within the NPXnY motif of the human angiotensin II type 1 receptor is involved in mediating signal transduction but is not essential for internalization. Mol. Pharmacol. 49, 89-95
18. Wrzal, P. K., Devost, D., Pétrin, D., Goupil, E., Iorio-Morin, C., Laporte, S. A., Zingg, H. H., and Hébert, T. E. (2012) Allosteric interactions between the oxytocin receptor and the β2-adrenergic receptor in the modulation of ERK1/2 activation are mediated by heterodimerization. Cell. Signal. 24, 342-350
19. Bolte, S., and Cordelières, F. P. (2006) A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 224, 213-232
20. Thorin, E. (1998) Functional cross-talk between endothelial muscarinic and α2-adrenergic receptors in rabbit cerebral arteries. Br. J. Pharmacol. 125, 1188-1193
21. Zimmerman, B., Beautrait, A., Aguila, B., Charles, R., Escher, E., Claing, A., Bouvier, M., and Laporte, S. A. (2012) Differential β-arrestin-dependent conformational signaling and cellular responses revealed by angiotensin analogs. Sci. Signal. 5, ra33
22. Dorn, G. W., 2nd, Becker, M. W., and Davis, M. G. (1992) Dissociation of the contractile and hypertrophic effects of vasoconstrictor prostanoids in vascular smooth muscle. J. Biol. Chem. 267, 24897-24905
23. de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W., and Unger, T. (2000) International Union of Pharmacology. XXIII. The Angiotensin II receptors. Pharmacol. Rev. 52, 415-472
24. Renna, N. F., de Las Heras, N., and Miatello, R. M. (2013) Pathophysiology of vascular remodeling in hypertension. Int. J. Hypertens. 808353
25. Berk, B. C., and Rao, G. N. (1993) Angiotensin II-induced vascular smooth muscle cell hypertrophy: PDGF A-chain mediates the increase in cell size. J. Cell. Physiol. 154, 368-380
26. Lavoie, C., Mercier, J. F., Salahpour, A., Umapathy, D., Breit, A., Villeneuve, L. R., Zhu, W. Z., Xiao, R. P., Lakatta, E. G., Bouvier, M., and Hébert, T. E. (2002) β1/β2-adrenergic receptor heterodimerization regulates β2-adrenergic receptor internalization and ERK signaling efficacy. J. Biol. Chem. 277, 35402-35410
27. Wrzal, P. K., Goupil, E., Laporte, S. A., Hébert, T. E., and Zingg, H. H. (2012) Functional interactions between the oxytocin receptor and the β2-adrenergic receptor: implications for ERK1/2 activation in human myometrial cells. Cell. Signal. 24, 333-341
28. Vilardaga, J. P., Nikolaev, V. O., Lorenz, K., Ferrandon, S., Zhuang, Z., and Lohse, M. J. (2008) Conformational cross-talk between α2A-adrenergic and μ-opioid receptors controls cell signaling. Nat. Chem. Biol. 4, 126-131
29. Hilairet, S., Bouaboula, M., Carrière, D., Le Fur, G., and Casellas, P. (2003) Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J. Biol. Chem. 278, 23731-23737
30. Herrera, M., Sparks, M. A., Alfonso-Pecchio, A. R., Harrison-Bernard, L. M., and Coffman, T. M. (2013) Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein. Hypertension 61, 253-258
31. MacDonald, M. L., Lamerdin, J., Owens, S., Keon, B. H., Bilter, G. K., Shang, Z., Huang, Z., Yu, H., Dias, J., Minami, T., Michnick, S. W., and Westwick, J. K. (2006) Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat. Chem. Biol. 2, 329-337
32. Gomes, I., Jordan, B. A., Gupta, A., Trapaidze, N., Nagy, V., and Devi, L. A. (2000) Heterodimerization of μ- and δ-opioid receptors: a role in opiate synergy. J. Neurosci. 20, RC110
33. Rocheville, M., Lange, D. C., Kumar, U., Patel, S. C., Patel, R. C., and Patel, Y. C. (2000) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288, 154-157
34. Rozenfeld, R., and Devi, L. A. (2010) Receptor heteromerization and drug discovery. Trends Pharmacol. Sci. 31, 124-130
35. Lavoie, C., and Hébert, T. E. (2003) Pharmacological characterization of putative β1-β2-adrenergic receptor heterodimers. Can. J. Physiol. Pharmacol. 81, 186-195
36. Goupil, E., Laporte, S. A., and Hébert, T. E. (2013) A simple method to detect allostery in GPCR dimers. Methods Cell Biol. 117, 165-179
37. Rozenfeld, R., Gupta, A., Gagnidze, K., Lim, M. P., Gomes, I., Lee-Ramos, D., Nieto, N., and Devi, L. A. (2011) AT1R-CB(1)R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J. 30, 2350-2363
38. Siddiquee, K., Hampton, J., McAnally, D., May, L., and Smith, L. (2013) The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br. J. Pharmacol. 168, 1104-1117
39. Lee, L. T., Ng, S. Y., Chu, J. Y., Sekar, R., Harikumar, K. G., Miller, L. J., and Chow, B. K. (2014) Transmembrane peptides as unique tools to demonstrate the in vivo action of a cross-class GPCR heterocomplex. FASEB J. 28, 2632-2644
40. Barki-Harrington, L., Luttrell, L. M., and Rockman, H. A. (2003) Dual inhibition of β-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation 108, 1611-1618
41. Whorton, M. R., Jastrzebska, B., Park, P. S., Fotiadis, D., Engel, A., Palczewski, K., and Sunahara, R. K. (2008) Efficient coupling of transducin to monomeric rhodopsin in a phospholipid bilayer. J. Biol. Chem. 283, 4387-4394
42. Han, Y., Moreira, I. S., Urizar, E., Weinstein, H., and Javitch, J. A. (2009) Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat. Chem. Biol. 5, 688-695
43. Fung, J. J., Deupi, X., Pardo, L., Yao, X. J., Velez-Ruiz, G. A., Devree, B. T., Sunahara, R. K., and Kobilka, B. K. (2009) Ligand-regulated oligomerization of β2-adrenoceptors in a model lipid bilayer. EMBO J. 28, 3315-3328
44. Breitwieser, G. E. (2004) G protein-coupled receptor oligomerization: implications for G protein activation and cell signaling. Circ. Res. 94, 17-27
45. Gurevich, V. V., and Gurevich, E. V. (2008) GPCR monomers and oligomers: it takes all kinds. Trends Neurosci. 31, 74-81
46. Lambert, N. A., and Javitch, J. A. (2014) CrossTalk opposing view: weighing the evidence for class A GPCR dimers, the jury is still out. J. Physiol. 592, 2443-2445
47. Bouvier, M., and Hébert, T. E. (2014) CrossTalk proposal: weighing the evidence for class A GPCR dimers, the evidence favours dimers. J. Physiol. 592, 2439-2441
48. Kenakin, T. (2010) G protein coupled receptors as allosteric proteins and the role of allosteric modulators. J. Recept. Signal. Transduct. Res. 30, 313-321
49. Kenakin, T. P. (2012) Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br. J. Pharmacol. 165, 1659-1669
50. Milligan, G., and Smith, N. J. (2007) Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends Pharmacol. Sci. 28, 615-620
51. Kern, A., Albarran-Zeckler, R., Walsh, H. E., and Smith, R. G. (2012) Apoghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism. Neuron 73, 317-332
52. q/11 in the striatum. Proc. Natl. Acad. Sci. U.S.A. 104, 654-659
53. Bourguet, C. B., Goupil, E., Tassy, D., Hou, X., Thouin, E., Polyak, F., Hébert, T. E., Claing, A., Laporte, S. A., Chemtob, S., and Lubell, W. D. (2011) Targeting the prostaglandin F2α receptor for preventing preterm labor with azapeptide tocolytics. J. Med. Chem. 54, 6085-6097
54. Dupré, D. J., Robitaille, M., Rebois, R. V., and Hébert, T. E. (2009) The role of Gβγ subunits in the organization, assembly, and function of GPCR signaling complexes. Annu. Rev. Pharmacol. Toxicol. 49, 31-56
55. Goupil, E., Laporte, S. A., and Hébert, T. E. (2013) GPCR heterodimers: asymmetries in ligand binding and signalling output offer new targets for drug discovery. Br. J. Pharmacol. 168, 1101-1103
56. Violin, J. D., DeWire, S. M., Yamashita, D., Rominger, D. H., Nguyen, L., Schiller, K., Whalen, E. J., Gowen, M., and Lark, M. W. (2010) Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J. Pharmacol. Exp. Ther. 335, 572-579